Life Science Success Podcast: Matt Hicks

Published: 1-Dec-2020
Ingredients Pharmaceutical

Federal Equipment's COO, Matt Hicks was recently interviewed by Don Davis on the Life Science Success podcast

The two discussed Matt’s career and how we at Federal Equipment buy and sell pharmaceutical equipment. Matt recently published an article titled “Reshoring a Nation’s API and Pharmaceutical Production”.

To listen to the podcast, click here or search for “Life Science Success” on your favourite podcast app. Or access the transcript by clicking here.

  • Companies:
  • Federal Equipment Company
See more

You may also like

Manufacturing

Virtual Pharma Expo set for September 2020

Read more
Featuring presentations from 20+ major pharmaceutical equipment manufacturers

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  2. Theranexus and Exeltis sign commercialisation agreement for neurological disorder-targeting TX01 The therapeutic will be used to target Gaucher and Niemann-Pick type C, with Exeltis attaining the exclusive rights to the marketing and distribution of TX01 across the Europe, South America and the Middle East
  3. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications
  4. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
  5. Mastering modified-release performance: excipient considerations Imagine a world where enhanced therapeutic efficacy, improved patient compliance and reduced adverse effects are tangible outcomes — even for drugs with short pharmacokinetic (PK) half-lives or narrow therapeutic indices. This is becoming a reality with modified-release (MR) oral delivery systems such as hydrophilic matrix tablets

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Manufacturing

Virtual Pharma Expo set for September 2020

Featuring presentations from 20+ major pharmaceutical equipment manufacturers
Manufacturing

Investor group purchases 110 acre pharmaceutical campus in Huntsville (Alabama, USA)

Diversified ultramodern pharmaceutical campus with solid dosage form, liquid manufacturing filling, distribution warehouse and vault storage; assets are available for purchase and/or lease
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535

Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
Distribution

Theranexus and Exeltis sign commercialisation agreement for neurological disorder-targeting TX01

The therapeutic will be used to target Gaucher and Niemann-Pick type C, with Exeltis attaining the exclusive rights to the marketing and distribution of TX01 across the Europe, South America and the Middle East
Regulatory

Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy

The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
Manufacturing

Novo Nordisk invests DKK 8.5bn into new Danish modular production site

This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications
Manufacturing

Reckitt expands US OTC manufacturing footprint with North Carolina facility

The site in Wilson will be responsible for producing Mucinex® branded tablets and liquids, which are designed as over the counter (OTC) medicines for cold and flu symptoms
Subscribe now